Clinical Trial Update: Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating anti-CD19 CAR-T cells for relapsed or refractory acute lymphoblastic leukemia and lymphomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphomas

Drugs mentioned

• Anti-CD19 CAR T cells (CD19-directed CAR T cells)

Snippet

Sponsor: The First Affiliated Hospital of Nanchang University | Conditions: Acute Lymphoblastic Leukemia ,Lymphomas | Phase 1, Phase 2 | Status: UNKNOWN